NAD+ versus NMN: what is the difference?

What is NAD+ and why is it important?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It plays a central role in energy production within the mitochondria—specifically in the electron transport chain that converts nutrients into ATP. Additionally, NAD+ is involved in DNA repair processes and signaling pathways studied in longevity research. The point is: NAD+ levels in the body decline with age, and this decrease is being investigated as a potential factor in age-related changes in cell function.

Interest in NAD+ supplementation grew significantly following research by scientists such as David Sinclair (Harvard), who studied the relationship between NAD+, sirtuins, and cellular aging. That research is ongoing and many questions remain, but the role of NAD+ in cellular energy metabolism is well established.

What is NMN?

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+. When taken orally, NMN is absorbed and converted by the body into NAD+. NMN was widely discussed in the longevity world after animal studies and initial human trials showed it could effectively increase NAD+ levels.

In Europe, however, NMN faces a significant regulatory issue. Following a Novel Foods application, the European Food Safety Authority (EFSA) has been assessing NMN. Several EU member states have restricted its sale pending full authorization. As a result, NMN is not legally available as a dietary supplement in all EU markets.

NAD+ versus NMN: the main differences

Mechanism of action NMN is a precursor—the body converts it into NAD+. NAD+ is the active molecule itself.
Conversion step Those who take NAD+ directly skip the conversion of NMN to NAD+; that step does not proceed with equal efficiency in everyone.
European status NAD+ is available as a dietary supplement in the EU. For NMN, Novel Foods restrictions apply in various EU countries.
Research base Both have been investigated in human studies. Research on NAD+ precursors is extensive; human data on NMN is more limited, but growing.

The European situation

For European consumers, the practical difference is significant. If you live in the Netherlands, Germany, Belgium, or another EU market and are looking to support the NAD+ pathway, NMN may not be legally available to you as a supplement. NAD+ itself is not subject to that same Novel Foods restriction.

That is why PPH offers NAD+ 300 mg instead of NMN: the active molecule, without regulatory uncertainty for European customers.

What the research shows

A randomized, triple-blind, placebo-controlled crossover study from the University of Washington (Xue et al., 2022, Nutrients) found that supplementation with an NAD+ precursor significantly increased NAD+ levels by 27% (p=0.033) and reduced blood glucose (p=0.013) in healthy middle-aged adults over a 7-day period. The study confirmed that oral NAD+ supplementation is safe and increases NAD+ levels.

A 2024 review article (PMC11205942, Nutrients) examined the variation in NAD+ supplementation and confirmed that liposomal delivery protects NAD+ precursors from enzymatic degradation in the gut.

The PPH approach

PPH NAD+ 300 mg provides 300 mg of NAD+ per capsule. As an endogenous coenzyme, NAD+ has no EFSA-approved health claim—we therefore factually describe it as "a coenzyme involved in cellular metabolism" and support that with peer-reviewed research rather than claims.

300 mg NAD+ per capsule
No Novel Foods uncertainty — available in EU markets
Plant-based HPMC capsule, GMO-free, without preservatives
Every batch checked in our certified Dutch production

Conclusion and next step

For European consumers who want to support the NAD+ pathway, NAD+ supplementation is a direct route that fits within regulations—without the Novel Foods uncertainty that surrounds NMN in the EU.

Because your vitality is not optional—it is essential.

Frequently asked questions

NMN is classified in the EU as a Novel Food—a substance without a significant history of use before 1997. Novel Foods require a safety assessment by EFSA before they can be marketed as supplements. Pending this, several member states have restricted sales.

Research on direct NAD+ supplementation shows that it effectively increases NAD+ levels. The conversion step required for NMN (NMN → NAD+) is not equally efficient for everyone, which can make direct NAD+ supplementation more consistent for some.

In the study by Xue et al. (2022), measurable increases in NAD+ levels were visible after 7 days of supplementation. Subjective experiences regarding energy and clarity are typically reported after 2 to 4 weeks of consistent use.

Sources

Xue Y. et al. (2022). A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD+ Metabolome. Nutrients, 14(11), 2219. DOI: 10.3390/nu14112219
PMC11205942 (2024). Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability. Nutrients.
EFSA (2023). Novel Foods — nicotinamide mononucleotide. www.efsa.europa.eu/